Skip to main content

Table 2 Clinical characteristics of the cohort and receptor status for patients with IHC testing

From: Data mining of digitized health records in a resource-constrained setting reveals that timely immunophenotyping is associated with improved breast cancer outcomes

Characteristic Total (%) With IHC testing (%)
Overall N = 402 N = 30
Sex
 Female 402 (100%) 30 (100%)
 Male 0 0
Age at diagnosis
  < 40 18 (4%) 3 (10%)
 40–49 62 (15%) 16 (53%)
 50–59 174 (43%) 7 (23%)
 60–69 127 (32%) 4 (13%)
 70+ 21 (5%) 0
BIRADS
 0,1,2 23 (6%) 18 (60%)
 3 203 (50%) 7 (23.3%)
 4,5,6 162 (40%) 4 (13.3%)
 unknown 14 (3%) 1 (3.3%)
Tumor stage
 I 85 (21%) 2 (7%)
 II 122 (30%) 12 (40%)
 III 84 (21%) 12 (40%)
 IV 19 (5%) 3 (10%)
 unknown 92 (23%) 1 (3%)
Patients without IHC testing 372 (93%) 0
Patients with IHC testing 30 (7%) 30 (100%)
ER testing
 positive n.a. 17 (57%)
 negative 11 (37%)
 unknown 2 (7%)
PR testing
 positive n.a. 16 (53%)
 negative 12 (40%)
 unknown 2 (7%)
HER2 testing
 positive n.a. 5 (17%)
 negative 23 (77%)
 unknown 2 (7%)
Additional IHC testing
 Ki67, P53 n.a. 1 (3%)
 unknown 29 (97%)
Subtype according to the Mexican Consensus [4]
 Luminal A n.a. 14 (47%)
 Luminal B 3 (10%)
 Basal-like/Triple negative 9 (30%)
 HER2 2 (7%)
 not enough information to assign 2 (7%)